Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00242762
Status:
COMPLETED
Last Update Posted:
2011-01-27
First Post:
2005-10-20
Brief Title:
ZD1839 IRESSA in Combination With Docetaxel Cisplatin in Subjects With Metastatic Head Neck Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase II Study to Evaluate the Safety and Efficacy of the Combination of ZD1839 IRESSA Docetaxel and Cisplatin in Subjects With Recurrent andor Metastatic Head and Neck Cancer
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to evaluate the activity of the combination ZD1839 docetaxel and cisplatin in subjects with recurrent andor metastatic head and neck cancer by estimating the objective response rate complete response CR and partial response PR at study closure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None